Your Location:Home >Products >127984-74-1

127984-74-1

  • Product Name:Somatuline
  • Molecular Formula:C56H73N11O12S2
  • Molecular Weight:1156.39
Inquiry

Product Details

pd_meltingpoint:>165°C (dec.)

Purity:99%

Fast Delivery High Purity Somatuline 127984-74-1 In Medicine

  • Molecular Formula:C2H4O2*C54H69N11O10S2
  • Molecular Weight:1156.39
  • Melting Point:>165°C (dec.) 
  • PSA:997.86000 
  • LogP:11.15110 

10-(4-aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide(Cas 127984-74-1) Usage

Description

Lanreotide acetate, an octapeptide somatostatin analog, reached its first worldwide market in France for acromegaly when surgery or radiotherapy have failed to restore normal growth hormone secretion. Lanreotide is a selective inhibitor of growth hormone and reduces the secretion of growth hormone, thyrotropin, motilin and pancreatic polypeptide in humans. Lanreotide has antiproliferative properties and is reportedly in clinical trials for the prevention of restenosis following coronary artery angioplasty, for diabetic retinopathy, and as a therapy for psoriasis. Its potential for neuroendocrine tumors and hormone-responsive prostate cancer has also been demonstrated.

Originator

Beaufour-Ipsen (France)

Uses

Lanreotide acetate has been used as an inhibitor to test the plasticity of hydrogen sulfide modulation by growth hormone/thyroid hormone signaling in wild-type mice.

Brand name

Somatuline LP

Biochem/physiol Actions

Lanreotide acetate is a somatostatin analog, a selective agonist for the SRIF-1 sst2 subtype of somatostatin receptor with a binding affinity of 0.8 nM for sst2 compared to 5.2 nM for sst5, 100 nM for sst3 and more than 1000 nM for the SRIF-2 subtypes, sst1 and sst4 receptors. It is used clinically in the management of acromegaly and symptoms caused by neuroendocrine tumors, and in recent studies can also inhibit tumor growth and has shown activity against non-endocrine tumors.

InChI:InChI=1/C54H69N11O10S2.C2H4O2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55;1-2(3)4/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74);1H3,(H,3,4)

127984-74-1 Relevant articles

SUBSTANTIALLY PURE LANREOTIDE OR ITS SALT and PROCESS THEREOF

-

Page/Page column 24, (2020/09/08)

The present invention provides substanti...

PROCESS FOR PREPARATION OF LANREOTIDE ACETATE

-

Page/Page column 21, (2019/05/10)

The invention relates to an improved met...

PROCESS FOR PREPARATION OF LANREOTIDE ACETATE

-

Page/Page column 9; 18; 19, (2017/11/10)

Disclosed herein is an improved 4+4 solu...

PROCESS FOR LANREOTIDE ACETATE PREPARATION

-

Page/Page column 21-22, (2018/01/15)

The invention relates to an improved met...

127984-74-1 Process route

C<sub>102</sub>H<sub>115</sub>N<sub>11</sub>O<sub>14</sub>S<sub>2</sub>

C102H115N11O14S2

acetic acid
64-19-7,77671-22-8

acetic acid

lanreotide acetate
2378114-72-6,127984-74-1

lanreotide acetate

Conditions
Conditions Yield
C102H115N11O14S2; With triethylsilane; methoxybenzene; trifluoroacetic acid; Cleland's reagent; In dichloromethane; at 25 - 30 ℃;
acetic acid; With iodine; In methanol; water; acetonitrile; at 15 - 30 ℃;
9.7 g
H-D-β-Nal-Cys-(Acm)-Tyr-D-Trp-Lys-Val-Cys(Acm)-Thr-NH<sub>2</sub>
1026080-86-3

H-D-β-Nal-Cys-(Acm)-Tyr-D-Trp-Lys-Val-Cys(Acm)-Thr-NH2

acetic acid
64-19-7,77671-22-8

acetic acid

[cycloS-S]-3-(2-naphthyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide acetate
2378114-72-6,127984-74-1

[cycloS-S]-3-(2-naphthyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide acetate

Conditions
Conditions Yield
With iodine; In methanol; water; acetonitrile; at 15 - 30 ℃;
12 g

127984-74-1 Upstream products

  • 64-19-7
    64-19-7

    acetic acid

  • 108736-35-2
    108736-35-2

    lanreotide

  • 1026080-86-3
    1026080-86-3

    H-D-β-Nal-Cys-(Acm)-Tyr-D-Trp-Lys-Val-Cys(Acm)-Thr-NH2

  • 631-61-8
    631-61-8

    ammonium acetate

Relevant Products